Literature DB >> 28093565

Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence.

M Baccarani1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28093565     DOI: 10.1038/leu.2017.20

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

Review 1.  Discontinuation of tyrosine kinase therapy in CML.

Authors:  Francois-Xavier Mahon
Journal:  Ann Hematol       Date:  2015-03-27       Impact factor: 3.673

2.  Moving treatment-free remission into mainstream clinical practice in CML.

Authors:  Timothy P Hughes; David M Ross
Journal:  Blood       Date:  2016-03-24       Impact factor: 22.113

3.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.

Authors:  Jorge E Cortes; Carmino Antonio De Souza; Manuel Ayala; Jose Luis Lopez; Eduardo Bullorsky; Sandip Shah; Xiaojun Huang; K Govind Babu; Kudrat Abdulkadyrov; José Salvador Rodrigues de Oliveira; Zhi-Xiang Shen; Tomasz Sacha; Israel Bendit; Zhizhou Liang; Tina Owugah; Tomasz Szczudlo; Sadhvi Khanna; Rafik Fellague-Chebra; Philipp D le Coutre
Journal:  Lancet Haematol       Date:  2016-12       Impact factor: 18.959

Review 5.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

6.  Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

Authors:  A Hochhaus; G Rosti; N C P Cross; J L Steegmann; P le Coutre; G Ossenkoppele; L Petrov; T Masszi; A Hellmann; L Griskevicius; W Wiktor-Jedrzejczak; D Rea; D Coriu; T H Brümmendorf; K Porkka; G Saglio; G Gastl; M C Müller; P Schuld; P Di Matteo; A Pellegrino; L Dezzani; F-X Mahon; M Baccarani; F J Giles
Journal:  Leukemia       Date:  2015-10-06       Impact factor: 11.528

Review 7.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113

8.  Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.

Authors:  A Hochhaus; G Saglio; T P Hughes; R A Larson; D-W Kim; S Issaragrisil; P D le Coutre; G Etienne; P E Dorlhiac-Llacer; R E Clark; I W Flinn; H Nakamae; B Donohue; W Deng; D Dalal; H D Menssen; H M Kantarjian
Journal:  Leukemia       Date:  2016-02-03       Impact factor: 11.528

Review 9.  The concept of treatment-free remission in chronic myeloid leukemia.

Authors:  S Saußele; J Richter; A Hochhaus; F-X Mahon
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

10.  Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.

Authors:  Timothy P Hughes; Jeffrey H Lipton; Nelson Spector; Francisco Cervantes; Ricardo Pasquini; Nelma Cristina D Clementino; Pedro Enrique Dorlhiac Llacer; Anthony P Schwarer; Francois-Xavier Mahon; Delphine Rea; Susan Branford; Das Purkayastha; LaTonya Collins; Tomasz Szczudlo; Brian Leber
Journal:  Blood       Date:  2014-06-19       Impact factor: 22.113

View more
  5 in total

1.  Chronic myeloid leukemia: room for improvement?

Authors:  Michele Baccarani; Fabrizio Pane; Gianantonio Rosti; Domenico Russo; Giuseppe Saglio
Journal:  Haematologica       Date:  2017-07       Impact factor: 9.941

2.  Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients.

Authors:  Stefania Stella; Silvia Rita Vitale; Fabio Stagno; Michele Massimino; Adriana Puma; Cristina Tomarchio; Maria Stella Pennisi; Elena Tirrò; Chiara Romano; Francesco Di Raimondo; Emma Cacciola; Rossella Cacciola; Livia Manzella
Journal:  Diagnostics (Basel)       Date:  2022-04-22

3.  Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.

Authors:  Michele Baccarani; Elisabetta Abruzzese; Vincenzo Accurso; Francesco Albano; Mario Annunziata; Sara Barulli; Germana Beltrami; Micaela Bergamaschi; Gianni Binotto; Monica Bocchia; Giovanni Caocci; Isabella Capodanno; Francesco Cavazzini; Michele Cedrone; Marco Cerrano; Monica Crugnola; Mariella D'Adda; Chiara Elena; Carmen Fava; Paola Fazi; Claudio Fozza; Sara Galimberti; Valentina Giai; Antonella Gozzini; Gabriele Gugliotta; Alessandra Iurlo; Gaetano La Barba; Luciano Levato; Alessandro Lucchesi; Luigia Luciano; Francesca Lunghi; Monia Lunghi; Michele Malagola; Roberto Marasca; Bruno Martino; Angela Melpignano; Maria Cristina Miggiano; Enrico Montefusco; Caterina Musolino; Fausto Palmieri; Patrizia Pregno; Davide Rapezzi; Giovanna Rege-Cambrin; Serena Rupoli; Marzia Salvucci; Rosaria Sancetta; Simona Sica; Raffaele Spadano; Fabio Stagno; Mario Tiribelli; Simona Tomassetti; Elena Trabacchi; Massimiliano Bonifacio; Massimo Breccia; Fausto Castagnetti; Fabrizio Pane; Domenico Russo; Giuseppe Saglio; Simona Soverini; Paolo Vigneri; Gianantonio Rosti
Journal:  Blood Adv       Date:  2019-12-23

4.  Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report.

Authors:  Isabella Capodanno; Elisabetta Lugli; Katia Codeluppi; Mariapina Faruolo; Enrica Bellesia; Riccardo Valli; Francesco Merli
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

Review 5.  Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia.

Authors:  Michele Baccarani; Francesca Bonifazi; Simona Soverini; Fausto Castagnetti; Gabriele Gugliotta; Wael Saber; Noel Estrada-Merly; Gianantonio Rosti; Robert Peter Gale
Journal:  Leukemia       Date:  2022-03-25       Impact factor: 12.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.